GestVision, Inc. focuses on innovative diagnostic technologies aimed at improving maternal and fetal health, particularly in the context of preeclampsia. The company has developed a point-of-care test known as the Congo Red Dot (CRD) test, which facilitates rapid identification and triage of preeclampsia during antenatal care. This test is designed to enhance clinical decision-making by providing timely results, thereby potentially improving outcomes for both mothers and their babies.

In addition to the CRD test, GestVision is engaged in advanced research involving proteomic profiling to identify specific biomarkers associated with preeclampsia. Their studies have highlighted the significance of protein misfolding and defective amyloid processing in the condition, with findings indicating that fragments of SERPINA1 and albumin can serve as reliable indicators of preeclampsia. This research underscores the company's commitment to leveraging scientific advancements to develop effective diagnostic tools that address critical health challenges in obstetrics.

United States

GestVision Inc. is a biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women's health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women's health by bringing forth premium products based upon robust scientific discoveries.

GestVision, Inc.

Company Details